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ischemia is frequent in ESRD patients and is a major predictor of mortality.
Interestingly the incidence of significant coronary stenosis (>70%) is low
when coronary angiography is performed suggesting other mechanisms such
as myocardial microvascular disease (MMD).
We are conducting a prospective observational study (NCT01291771)
evaluating the incidence of major adverse cardiac events (MACE) in ESRD
patients with proven MMD and no history of coronary disease. 105 patients
with positive test for myocardial ischemia will be explored by coronary angi-
ography. Detection of MMD will be performed simultaneously with a pressure
sensor/thermistor-tipped guidewire in the left anterior descending (LAD), the
left circumflex (LCX) and the right coronary artery (RCA). We will measure
Fractional Flow Reserve (FFR) and Coronary Flow Reserve (CFR) allowing
calculation of the Index of Microcirculatory Resistance (IMR). These patients
will be compared in a 2 years follow-up for the incidence of MACE with 105
ESRD patients without myocardial ischemia on non invasive testing. 
We are reporting the preliminary data of patients (n=6) in whom invasive
MMD evaluation was performed. Mean age 63±8 years, sex ratio=1, diabetic
nephropathy=1, under dialysis=4. 1 patient had significant coronary stenosis,
the others had normal angiograms (32%) or non-significant coronary atheroma
(50%). In patients without significant coronary stenosis, mean FFR was
0.93±0.02 (LAD), 0.98±0.02 (LCX) and 0.95±0.02 (RCA). Mean CFR was
3.3±2.7 (LAD), 2.3±1.1 (LCX) and 3.1±1.4 (RCA). Mean IMR was 19±6
(LAD), 27±15 (LCX) and 30±26 (RCA).
Preliminary data suggest impaired myocardial microvascular function in
ESRD patients with positive test for myocardial ischemia and non significant
coronary artery stenosis.
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Objectives: The aim of this investigation was to test the diagnostic addi-
tive value of the C-Terminal Provasopressin (Copeptin) an indirect marker for
arginin-vasopressin (AVP) in the detection of STEMI patients presenting early
(<6 hours after the Symptom Onset (SO). 
Methods: We measured plasma copeptin in 464 consecutive STEMI
patients (78% men, mean age 63 ± 14 years) immediately after the sheath
insertion and before the primary PCI. Of those patients 200 (43.1%) had a
blood sampling early after SO (<6 hours) and were included in this analysis.
Using the previously established threshold of 4.8pmol/L for copeptin and the
local 99th of the upper limit of the normal value for troponin I (0.15μg/L) we
evaluated the additive value of the combination of copeptin and troponin I in
this AMI patients. 
Results: In the 200 Early STEMI presenters, the median time between SO
and blood sample was 165 minutes; IQR [125-230], (min 35-max 360). The
median value of Troponin I at sheath insertion was 0.59 μg/L; IQR [0.13-3.2]
and 33.1 pmol/L, IQR [11.6-111] for copeptin. Troponin I was negative at
admission in n=56 (28%) STEMI patients and copeptin was negative at admis-
sion in n=54 (27%) STEMI patients. Patients with one or two negative bio-
markers presented earlier than those with both positive biomarker (median
time in minutes 152 [127-218] vs. 180 [125-240]). Among the n=56 patients
with a negative troponin value at admission, n=38 (67.8%) had a positive
copeptin value (>4.8pmol/L).
Therefore, when copeptin is combined to troponin I, the proportion of
STEMI patients non-detected was reduced from 28% to a remaining 9.2%
(p<0.001) of very early presenters (median time of 145 min IQR [116-180]).
Conclusions: The combination of copeptin and troponin improves the
diagnostic value in AMI patients but cannot rule out the diagnosis of acute
STEMI in very early presenters (<3 hours).
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Introduction: Paraoxonases (PONs) are closely related antioxidant
enzymes encoded by clustered genes on chromosome 7q. Two particular poly-
morphisms, namely PON1-192 and PON2-311, in the genes encoding the anti-
oxidant enzymes paraoxonase-1 (PON1) and paraoxonase-2 (PON2) have
been associated with an increased risk of acute myocardial infarction (AMI).
However, previous findings have been contradictory. We evaluated three PON
polymorphisms (PON1 Leu55Met and Gln192Arg; PON2 Ser311Cys) in
Tunisian patients with AMI.
Methods: 168 AMI patients compared to 169 healthy volunteers.
Results: PONs allele and genotype frequencies did not differ between
patients and controls. 
The PON polymorphisms (PON1 Leu55Met and Gln192Arg; PON2
Ser311Cys) were not significantly associated with AMI (p=1.11, p=0.09,
p=1.46 respectively). No significant differences in age, sex, BMI, waist cir-
cumference, total Cholesterol, HDL-C and LDL-C were detected among the
three-genotype subgroups of PON1 Leu55Met, PON1 Gln192Arg and PON2
Ser311Cys in the AMI patients.
Conclusions: The PON1 Leu55Met, PON1 Gln192Arg and PON2 Ser311Cys
polymorphisms are not related to acute myocardial infarction in Tunisian population
052
Acute coronary syndrome features with Fourier domain optical cohe-
rence tomography 
Righab Hamdan [Orateur] , Nicolas Amabile, Said Ghostine, Sami Ham-
mas, Maria Rosa Ghigna
Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France
Background and aim: Fourier domain Optical Coherence Tomography
(FD-OCT) is a new imaging modality characterized by a high axial resolution
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